NVCT Nuvectis Pharma Inc.

Nuvectis Pharma Inc.

Biotechnology: Pharmaceutical Preparations

Health Care

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

IPO Year: 2022

Exchange: NASDAQ

Website: https://www.nuvectis.com

Recent Analyst Ratings for Nuvectis Pharma Inc.

Date	Price Target	Rating	Analyst
7/13/2022	$21.00	Buy	Ladenburg Thalmann
3/2/2022	$14.00	Buy	HC Wainwright & Co.

See more ratings

Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
Fort Lee, NJ, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium. Event2024 Ladenburg Virtual Oncology Innovators & Investors SymposiumDate12 December 2024Time10 am EST About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicin
12/10/24 8:00:00 AM ET
$NVCT
Biotechnology: Pharmaceutical Preparations
Health Care
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
NXP800 demonstrated single agent activity New dosing schedule successfully minimized thrombocytopenia Fort Lee, NJ, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer. Platinum-resistant, ARID1a-mutated ovarian cancer is a serious condition that carries a poor prognosis with an estimated life expectancy of approximately one year from diagnosis.
11/14/24 7:00:00 AM ET
$NVCT
Biotechnology: Pharmaceutical Preparations
Health Care
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancersNXP900 Phase 1a dose escalation study progressing as planned, 4 escalation cohorts completed with no DLTs, dose escalation continues FORT LEE, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter
11/5/24 7:00:21 AM ET
$NVCT
Biotechnology: Pharmaceutical Preparations
Health Care
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
Nuvectis Pharma (NASDAQ:NVCT) continues to make strides in precision oncology, gaining momentum following presentations last week at the AACR-NCI-EORTC Symposium where its drug candidate NXP900 demonstrated strong synergy with ALK inhibitors in non-small cell lung cancer (NSCLC) cells that despite being driven by ALK fusions, are resistant to treatment with the market leading ALK Inhibitors, alectinib and lorlatinib, showcasing NXP900's potential to address resistance mechanisms in NSCLC. Also, with the growing anticipation of the data update from NXP800 expected soon from the Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, Nuvectis is positioning itself at the forefron
10/28/24 8:21:00 AM ET
$NUVL
$NVCT
$SMMT
Biotechnology: Pharmaceutical Preparations
Health Care
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
Fort Lee, NJ, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming scientific presentations for NXP900 at the 2024 AACR-NCI-EORTC on Molecular Targets and Cancer Therapeutics (October 23-25, 2024, Barcelona, Spain). Titles and Presenters Presentation Details Title NXP900, a novel YES1/SRC kinase inhibitor in phase 1 dose escalation, demonstrates potent synergy with ALK inhibitors in ALK resistant cell lines Presenter Asier Unciti-Broce
10/23/24 8:00:00 AM ET
$NVCT
Biotechnology: Pharmaceutical Preparations
Health Care
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Fort Lee, NJ , Oct. 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference taking place on October 9, 2024 in New York, NY. Event Annual ROTH Healthcare Opportunities Conference Panel Title Innovative Therapies for Solid Tumors Date and Time October 9, 2024, 12:30 pm ET About Nuvectis Phar
10/7/24 8:00:00 AM ET
$NVCT
Biotechnology: Pharmaceutical Preparations
Health Care
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
With its focus on targeting well-defined subgroups by inhibiting SRC/YES1 kinases in Non Small-Cell Lung Cancer patients resistant to EGFR and ALK targeted therapies, Nuvectis Pharma's NXP900 could hold similar transformative potential in NSCLC as Summit Therapeutics's Ivonescimab The Bottom Line Summit Therapeutics (NASDAQ:SMMT) recently reported Ivonescimab's Phase 3 results from study conducted in China that showed significant efficacy in addressing NSCLC treatment resistance, surpassing Merck's Keytruda in key outcomes and sending SMMT stock skyrocketing. Like Ivonescimab, Nuvectis Pharma's (NASDAQ:NVCT) NXP900 tackles resistance in NSCLC but targets a different pathway by inhibiti
9/16/24 7:15:00 AM ET
$MRK
$NVCT
$SMMT
Biotechnology: Pharmaceutical Preparations
Health Care
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Fort Lee, NJ, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference. EventH.C. Wainwright Global Investment ConferenceDateSeptember 9, 2024Time12:00 PM ETLinkhttps://journey.ct.events/view/5bacb2fb-d0c8-4efa-92b8-7365c030ddd5 About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development
9/5/24 8:00:00 AM ET
$NVCT
Biotechnology: Pharmaceutical Preparations
Health Care
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
FORT LEE, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that NXP800 was granted Orphan Drug Designation by the United States Food and Drug Administration ("FDA") for the treatment of AT-rich interactive domain-containing protein 1a (ARID1a) ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "We are very pleased to have received this designati
8/29/24 8:00:42 AM ET
$NVCT
Biotechnology: Pharmaceutical Preparations
Health Care
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
FORT LEE, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the second quarter 2024 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "During the second quarter we continued to advance our clinical trials for NXP800 and NXP900. For NXP800, the Phase 1b clinical trial in platinum resistant, ARID1a-mutated ovarian cancer is continuing to enroll
8/6/24 8:28:42 AM ET
$NVCT
Biotechnology: Pharmaceutical Preparations
Health Care

Nuvectis Pharma Inc.

Recent Analyst Ratings for Nuvectis Pharma Inc.

Nuvectis Pharma Inc.

Recent Analyst Ratings for Nuvectis Pharma Inc.

Nuvectis Pharma Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chairman & CEO Bentsur Ron bought $20,925 worth of shares (4,500 units at $4.65), increasing direct ownership by 0.14% to 3,270,924 units (SEC Form 4)

Amendment: Large owner Mosseri Marlio Charles bought $228,941 worth of shares (49,121 units at $4.66), increasing direct ownership by 2% to 2,644,121 units (SEC Form 4)

Large owner Mosseri Marlio Charles bought $79,900 worth of shares (17,000 units at $4.70), increasing direct ownership by 0.66% to 2,612,000 units (SEC Form 4)

Chief Science & Business Off Poradosu Enrique bought $9,980 worth of shares (2,000 units at $4.99), increasing direct ownership by 0.13% to 1,506,319 units (SEC Form 4)

Chairman & CEO Bentsur Ron bought $98,400 worth of shares (20,000 units at $4.92), increasing direct ownership by 0.62% to 3,266,424 units (SEC Form 4)

Bentsur Ron bought $13,076 worth of shares (1,940 units at $6.74), increasing direct ownership by 0.06% to 3,246,424 units (SEC Form 4)

Bentsur Ron bought $12,800 worth of shares (2,000 units at $6.40), increasing direct ownership by 0.06% to 3,244,484 units (SEC Form 4)

Poradosu Enrique bought $3,145 worth of shares (500 units at $6.29), increasing direct ownership by 0.03% to 1,504,319 units (SEC Form 4)

Shemesh Shay bought $7,034 worth of shares (1,113 units at $6.32), increasing direct ownership by 0.07% to 1,493,068 units (SEC Form 4)

Bentsur Ron bought $51,450 worth of shares (5,000 units at $10.29), increasing direct ownership by 0.15% to 3,242,484 units (SEC Form 4)

Nuvectis Pharma Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Ladenburg Thalmann initiated coverage on Nuvectis Pharma with a new price target

HC Wainwright & Co. initiated coverage on Nuvectis Pharma with a new price target

Nuvectis Pharma Inc. Press Releases

Fastest customizable press release news feed in the world

Nuvectis Pharma Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics

Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch

Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

Amendment: SEC Form SC 13G/A filed by Nuvectis Pharma Inc.

SEC Form SC 13G/A filed by Nuvectis Pharma Inc. (Amendment)

SEC Form SC 13G filed by Nuvectis Pharma Inc.

SEC Form SC 13G/A filed by Nuvectis Pharma Inc. (Amendment)

SEC Form SC 13G/A filed by Nuvectis Pharma Inc. (Amendment)

SEC Form SC 13G/A filed by Nuvectis Pharma Inc. (Amendment)

SEC Form SC 13G filed by Nuvectis Pharma Inc.

SEC Form SC 13G filed by Nuvectis Pharma Inc.

SEC Form SC 13G filed by Nuvectis Pharma Inc.

SEC Form SC 13G/A filed by Nuvectis Pharma Inc. (Amendment)

Nuvectis Pharma Inc. SEC Filings

SEC Form S-8 filed by Nuvectis Pharma Inc.

SEC Form 10-Q filed by Nuvectis Pharma Inc.

Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Nuvectis Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Nuvectis Pharma Inc.

Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Nuvectis Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form 10-Q filed by Nuvectis Pharma Inc.

Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEFA14A filed by Nuvectis Pharma Inc.

Nuvectis Pharma Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Dev. & Ops. Officer Shemesh Shay was granted 150,000 shares, increasing direct ownership by 10% to 1,643,068 units (SEC Form 4)

Chief Science & Business Off Poradosu Enrique was granted 150,000 shares, increasing direct ownership by 10% to 1,656,319 units (SEC Form 4)

Vice President, Finance Carson Michael J. was granted 51,000 shares, increasing direct ownership by 58% to 138,918 units (SEC Form 4)

Chairman & CEO Bentsur Ron was granted 250,000 shares, increasing direct ownership by 8% to 3,520,924 units (SEC Form 4)

Chairman & CEO Bentsur Ron bought $20,925 worth of shares (4,500 units at $4.65), increasing direct ownership by 0.14% to 3,270,924 units (SEC Form 4)

Amendment: Large owner Mosseri Marlio Charles bought $228,941 worth of shares (49,121 units at $4.66), increasing direct ownership by 2% to 2,644,121 units (SEC Form 4)

Large owner Mosseri Marlio Charles bought $79,900 worth of shares (17,000 units at $4.70), increasing direct ownership by 0.66% to 2,612,000 units (SEC Form 4)

Chief Science & Business Off Poradosu Enrique bought $9,980 worth of shares (2,000 units at $4.99), increasing direct ownership by 0.13% to 1,506,319 units (SEC Form 4)

Chairman & CEO Bentsur Ron bought $98,400 worth of shares (20,000 units at $4.92), increasing direct ownership by 0.62% to 3,266,424 units (SEC Form 4)

Vice President, Finance Carson Michael J. sold $22,478 worth of shares (2,755 units at $8.16) and was granted 63,373 shares, increasing direct ownership by 222% to 87,918 units (SEC Form 4)